Soleno Faces Securities Class Action Over DCCR Safety as Investors Weigh May 5 Lead‑Plaintiff Deadline

Overview

• A federal class action has been filed in the Northern District of California, captioned City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc., No. 3:26‑cv‑01979.
• Rosen Law Firm, Hagens Berman, Kessler Topaz, Pomerantz, and Robbins LLP are recruiting shareholders who bought SLNO between March 26 and November 4 or 5, 2025, with May 5, 2026 set as the deadline to seek lead‑plaintiff status, and notices state no class has been certified.
• The complaints say Soleno misled investors by downplaying Phase 3 safety signals for DCCR, including excess fluid retention, and by overselling the drug’s commercial prospects after launch.
• Concerns surfaced after Scorpion Capital’s August 15, 2025 report alleging unsafe use in children, hospitalizations, shaky launch metrics, and data irregularities, which was followed by a same‑day share drop.
• Soleno disclosed in a September 10, 2025 SEC Form 8‑K that a patient died after taking DCCR, and in early November 2025 it reported fewer new starts and higher discontinuations following the August report, which preceded a roughly 26% one‑day decline.